Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.65 |
| ▸ | GABRD | O14764 | 2/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.65 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.65 |
| ▸ | GABRE | P78334 | 2/20 | 0.65 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.65 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.65 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.65 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037012 | 1.00 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL288345 | 1.00 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7350338 | 0.86 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7353965 | 0.86 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1427397 | 0.86 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1162283 | 0.85 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18980778 | 0.85 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL26547294 | 0.84 | ALDH1A1 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8513633 | 0.84 | GABRP (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15871670 | 0.83 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| EP-3697208-B1 | HIGH-FIDELITY LONG-TERM STORAGE OF BIOLOGICAL MATERIAL | CENTRE NAT RECH SCIENT (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4622993-A1 | PEPTIDE WITH ANTIMICROBIAL ACTIVITY | Freie Universität Berlin (DE) | 2025-10-01 | — | — | EP | disclosed |
| US-12250944-B2 | High-fidelity long-term storage of biological material | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-03-18 | — | — | US | disclosed |
| US-20240350657-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2024-10-24 | — | — | US | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| EP-3856258-B1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PF MEDICAMENT (FR) | 2024-07-31 | — | — | EP | disclosed |
| US-12011485-B2 | Sulfomaleimide-based linkers and corresponding conjugates | PIERRE FABRE MEDICAMENT (FR) | 2024-06-18 | — | — | US | disclosed |
| WO-2024110532-A1 | PEPTIDE WITH ANTIMICROBIAL ACTIVITY | FREIE UNIVERSITÄT BERLIN (DE) | 2024-05-30 | — | — | WO | disclosed |
| EP-1966198-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDOÝ3,4-D¨PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BAXTER ELLEN E | 2007-11-08 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| WO-2007050612-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-4812163-A | Phenoxyacetic acids and herbicides comprising them as active ingredients | TEIJIN, LIMITED (JP) | 1989-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | GABRP 2657/4885GABRD 3899/4885GABRA1 3231/4885 |
| US-12011485-B2 | Sulfomaleimide-based linkers and corresponding conjugates | CSGALNACT1, CD44, IGLV6-57 | GABRP 294/4885GABRD 1033/4885GABRA1 815/4885 |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | IGF1R, CD44, MUC1 | GABRP 250/4885GABRD 807/4885GABRA1 242/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | GABRP 2211/4885GABRD 2036/4885GABRA1 2691/4885 |
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | GABRP 976/4885GABRD 1797/4885GABRA1 2011/4885 |
| US-20240350657-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | STS, SULT1E1, CD44 | GABRP 436/4885GABRD 1798/4885GABRA1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.